CD45 glycosylation controls T-cell life and death

Immunology and Cell Biology

Volumn 86, Issue 7, 2008, Pages 608-615

  Earl, L A ^a   Baum, L G ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

CD45; Galectin; Glycan; Lectin; Phosphatase; T cell

Indexed keywords

CARBOHYDRATE BINDING PROTEIN; CD45 ANTIGEN; GALECTIN; PROTEIN TYROSINE PHOSPHATASE; T LYMPHOCYTE ANTIGEN;

APOPTOSIS; CELL DEATH; CELL DIFFERENTIATION; CELL MATURATION; CELL SURVIVAL; CYTOPLASM; GLYCOSYLATION; HUMAN; IMMUNE FUNCTION TEST; NONHUMAN; REVIEW; SIGNAL TRANSDUCTION; T LYMPHOCYTE;

ANIMALS; ANTIGENS, CD45; CELL DEATH; GLYCOSYLATION; HUMANS; LECTINS; LYMPHOCYTE ACTIVATION; T-LYMPHOCYTES;

EID: 53249142239     PISSN: 08189641     EISSN: 14401711     Source Type: Journal    
DOI: 10.1038/icb.2008.46     Document Type: Review

References (106)

1. Thomas ML. The leukocyte common antigen family. Annu Rev Immunol 1989; 7: 339-369.
2. Mee PJ, Turner M, Basson MA, Costello PS, Zamoyska R, Tybulewicz VLJ. Greatly reduced efficiency of both positive and negative selection of thymocytes in CD45 tyrosine phosphatase-deficient mice. Eur J Immunol 1999; 29: 2923-2933.
3. + thymocytes, and in B cell maturation. J Exp Med 1996; 183: 1707-1718.
4. Kisihara K, Penninger J, Wallace VA, Kündig TM, Kawai K, Wakeham A et al. Normal B lymphocyte development but impaired T cell maturation in CD45-exon6 protein tyrosine phosphatase-deficient mice. Cell 1993; 74: 143-156.
5. Hermiston ML, Xu Z, Weiss A. CD45: a critical regulator of signaling thresholds in immune cells. Annu Rev Immunol 2003; 21: 107-137.
6. Iida N, Lokeshwar VB, Bourguignon LYW. Mapping the fodrin binding domain in CD45, a leukocyte membrane-associated tyrosine phosphatase. J Biol Chem 1994; 269: 28576-28583.
7. Lokeshwar VB, Bourguignon LYW. Tyrosine phosphatase activity of lymphoma CD45 (GP180) is regulated by a direct interaction with the cytoskeleton. J Biol Chem 1992; 267: 21551-21557.
8. Pradhan D, Morrow JS. The spectrin-ankyrin skeleton controls CD45 surface display and interleukin-2 production. Immunity 2002; 17: 303-315.
9. + T cells results from de novo synthesis of CD45 glycans. J Biol Chem 2004; 279: 36689-36697.
10. Amano M, Galvan M, He J, Baum LG. The ST6Gal I sialyltransferase selectively modifies N-glycans on CD45 to negatively regulate galectin-1-induced CD45 clustering, phosphatase modulation, and T cell death. J Biol Chem2003; 278: 7469-7475.
11. Baum LG, Derbin K, Perillo NL, Wu T, Pang M, Uittenbogaart C. Characterization of terminal sialic acid linkages on human thymocytes. J Biol Chem 1996; 271: 10793-10799.
12. Blander JM, Visintin I, Janeway Jr CA, Medzhitov R. a(1,3)- Fucosyltransferase VII and a(2,3)-sialyltransferase IV are up-regulated in activated CD4 T cells and maintained after their differentiation into Th1 and migration into inflammatory sites. J Immunol 1999; 163: 3746-3752.
13. + T lymphocytes leads to dramatic remodeling of N-linked glycans. J Immunol 2006; 177: 2431-2440.
14. Furukawa K, Funakoshi Y, Autero M, Horejsi V, Kobata A, Gahmberg CG. Structural study of the O-linked sugar chains of human leukocyte tyrosine phosphatase CD45. Eur J Biochem 1998; 251: 288-294.
15. + T cells from naïve cells. J Immunol 1998; 161: 641-648.
16. Grabie N, Delfs MW, Lim YC, Westrich JR, Luscinskas FW, Lichtman AH. β-Galactoside α2,3-sialyltransferase-I gene expression during Th2 but not Th1 differentiation: implications for core2-glycan formation on cell surface proteins. Eur J Immunol 2002; 32: 2766-2772.
17. Hernandez JD, Klein J, Van Dyken SJ, Marth JD, Baum LG. T-cell activation results in microheterogenous changes in glycosylation of CD45. Int Immunol 2007; 19: 847-856.
18. Leitenberg D, Boutin Y, Lu DD, Bottomly K. Biochemical association of CD45 with the T cell receptor complex: regulation by CD45 isoform and during T cell activation. Immunity 1999; 10: 701-711.
19. Moore GT, Brown SJ, Winterhalter AC, Lust M, Salvaris EJ, Selan C et al. Glycosylation changes in hFUT1 transgenic mice increase TCR signaling and apoptosis resulting in thymocyte maturation arrest. Mol Immunol 2008; 45: 2401-2410.
20. Nguyen JT, Evans DP, Galvan M, Pace KE, Leitenberg D, Bui TN et al. CD45 modulates galectin-1-induced T cell death: regulation by expression of core 2 O-glycans. J Immunol 2001; 167: 5697-5707.
21. Novak TJ, Farber D, Leitenberg D, Hong S, Johnson P, Bottomly K. Isoforms of the transmembrane tyrosine phosphatase CD45 differentially affect T cell recognition. Immunity 1994; 1: 109-119.
22. Ohta T, Kitamura K, Maizel AL, Takeda A. Alterations in CD45 glycosylation pattern accompanying different cell proliferation states. Biochem Biophys Res Commun 1994; 200: 1283-1289.
23. + T lymphocyte homeostasis by modulating O-glycan biosynthesis. Immunity 2000; 12: 273-283.
24. Thomas ML, Reynolds PJ, Chain A, Ben-Neriah Y, Trowbridge IS. B-cell variant of mouse T200 (Ly-5): evidence for alternative mRNA splicing. Proc Nat Acad Sci USA 1987; 84: 5360-5363.
25. Chui D, Ong CJ, Johnson P, Ten HS, Marth JD. Specific CD45 isoforms differentially regulate T cell receptor signaling. EMBO J 1994; 13: 798-807.
26. Daniels MA, Hogquist KA, Jameson SC. Sweet 'n' sour: the impact of differential glycosylation on T cell responses. Nat Immunol 2002; 3: 903-910.
27. Toscano MA, Bianco GA, Ilarregui JM, Croci DO, Correale J, Hernandez JD et al. Differential glycosylation of Th1, Th2, and Th-17 effector cells selectively regulates susceptibility to cell death. Nat Immunol 2007; 8: 825-834.
28. Tsuboi S, Fukuda M. Overexpression of branches O-linked oligosaccharides on T cell surface glycoproteins impairs humoral immune responses in transgenic mice. J Biol Chem 1998; 273: 30680-30687.
29. Van Vliet SJ, Gringhuis SI, Geijtenbeek TBH, van Kooyk Y. Regulation of effector T cells by antigen-presenting cells via interaction of the C-type lectin MGL with CD45. Nat Immunol 2006; 7: 1200-1208.
30. Galvan M, Tsuboi S, Fukuda M, Baum LG. Expression of a specific glycosyltransferase enzyme regulates T cell death mediated by galectin-1. J Biol Chem 2000; 275: 16730-16737.
31. Felberg J, Lefebvre DC, Lam M, Wang Y, Ng DHW, Birkenhead D et al. Subdomain X of the kinase domain of Lck binds CD45 and facilitates dephosphorylation. J Biol Chem 2004; 279: 3455-3462.
32. Maksumova L, Wang Y, Wong NKY, Le HT, Pallen CJ, Johnson P. Differential function of PTPα and PTPαY789F in T cells and regulation of PTPα phosphorylation at Tyr-789 by CD45. J Biol Chem 2007; 282: 20925-20932.
33. Mustelin T, Williams S, Tailor P, Couture C, Zenner G, Burn P et al. Regulation of the p70zap tyrosine protein kinase in T cells by the CD45 phosphotyrosine phosphatase. Eur J Immunol 1995; 25: 942-946.
34. Falahati R, Leitenberg D. Changes in the role of the CD45 protein tyrosine phosphatase in regulating Lck tyrosine phosphorylation during thymic development. J Immunol 2007; 178: 2056-2064.
35. Lefebvre DC, Felberg J, Cross JL, Johnson P. The noncatalytic domains of Lck regulate its dephosphorylation by CD45. Biochim Biophys Acta 2003; 1650: 40-49.
36. Wang Y, Johnson P. Expression of CD45 lacking the catalytic protein tyrosine phosphatase domain modulates Lck phosphorylation and T cell activation. J Biol Chem 2005; 280: 14318-14324.
37. Pace KE, Lee C, Stewart PL, Baum LG. Restricted receptor segregation into membrane microdomains occurs on human T cells during apoptosis induced by galectin-1. J Immunol 1999; 163: 3801-3811.
38. Jackson DI, Barclay AN. The extra segments of sequence in rat leucocyte common antigen (L-CA) are derived by alternative splicing of only three exons and show extensive O-linked glycosylation. Immunogenetics 1989; 29: 281-287.
39. 2-terminus. EMBO J 1987; 6: 1259-1264.
40. Cyster JG, Fowell D, Barclay AN. Antigenic determinants encoded by alternatively spliced exons of CD45 are determined by the polypeptide but influenced by glycosylation. Int Immunol 1994; 6: 1875-1881.
41. Irles C, Symons A, Michel F, Bakker TR, van der Merwe PA, Acuto A. CD45 ectodomain controls interaction with GEMs and Lck activity for optimal TCR signaling. Nat Immunol 2003; 4: 189-197.
42. Majeti R, Bilwes AM, Noel JP, Hunter T, Weiss A. Dimerization-induced inhibition of receptor protein tyrosine phosphatase function through an inhibitory wedge. Science 1998; 279: 88-91.
43. Sato T, Furukawa K, Autero M, Gahmberg CG, Kobata A. Structural study of the sugar chains of human leukocyte common antigen CD45. Biochemistry 1993; 32: 12694-12704.
44. Pulido R, Sánchez-Madrid F. Glycosylation of CD45: carbohydrate processing through Golgi apparatus is required for cell surface expression and protein stability. Eur J Immunol 1992; 22: 43-468.
45. Hathcock KS, Laszlo G, Dickler HB, Sharrow SO, Johnson P, Trowbridge IS et al. Expression of variable exon A-, B-, and C-specific CD45 determinants on peripheral and thymic T cell populations. J Immunol 1992; 148: 19-28.
46. Trowbridge IS, Thomas ML. CD45: an emerging role as a protein tyrosine phosphatase required for lymphocyte activation and development. Annu Rev Immunol 1994; 12: 85-116.
47. Pulido R, Schlossman SF, Saito H, Streuli M. Identification of amino acids at the junction of exons 3 and 7 that are used for the generation of glycosylation-related human CD45RO and CD45RO-like antigen specificities. J Exp Med 1994; 179: 1035-1040.
48. McNeill L, Cassady RL, Sarkardei S, Cooper JC, Morgan G, Alexander DR. CD45 isoforms in T cell signalling and development. Immunol Lett 2004; 92: 125-134.
49. McNeill L, Salmond RJ, Cooper JC, Carret CK, Cassady-Cain RL, Roche-Molina M et al. The differential regulation of Lck kinase phosphorylation sites by CD45 is critical for T cell receptor signaling responses. Immunity 2007; 27: 425-437.
50. Merkenschlager M, Beverly PCL. Evidence for differential expression of CD45 isoforms by precursors for memory-dependent and independent cytotoxic responses: human CD8 memory CTLp selectively express CD45R0 (UCHL1). Int Immunol 1989; 1: 450-459.
51. Zola H, Melo JV, Zowtyj HN, Nikoloutsopoulos A, Skinner J. The leukocyte-common antigen (CD45) complex and B-lymphocyte activation. Hum Immunol 1990; 27: 368-377.
52. Varki A, Cummings R, Esko J, Freeze H, Hart G, Marth J (eds). Essentials of Glycobiology. Cold Spring Harbor Laboratory Press: New York, 1999, pp 30-42.
53. Holmes N. CD45: all is not yet crystal clear. Immunology 2006; 117: 145-155.
54. Uemura K, Yokota Y, Kozutsumi Y, Kawasaki T. A unique CD45 glycoform recognized by the serum mannan-binding protein in immature thymocytes. J Biol Chem 1996; 271: 4581-4584.
55. Dalziel M, Whitehouse C, McFarlane I, Brockhausen I, Gschmeissner S, Schwientek T et al. The relative activities of the C2GnT1 and ST3Gal-I glycosyltransferases determine O-glycan structure and expression of a tumor-associated epitope on MUC1. J Biol Chem 2001; 276: 11007-11015.
56. Baba M, Ma BY, Nonaka M, Matsuishi Y, Hirano M, Nakamura N et al. Glycosylation-dependent interaction of Jacalin with CD45 induces T lymphocyte activation and Th1/ Th2 cytokine secretion. J Leuk Biol 2007; 81: 1002-1011.
57. Monostori É, Hartyáni Z, Hegedüs Z, Oscovszki I, Pállinger É, Andó I. Microheterogeneity of the cell surface tyrosine phosphatase, CD45RA, on T cells: phytohaemagglutinin binding and non-binding fraction of the 220 kDa isoform. Immunol Lett 1997; 59: 171-176.
58. Garcia GG, Berger SB, Sadighi Akha AA, Miller RA. Age-associated changes in glycosylation of CD43 and CD45 on mouse CD4 T cells. Eur J Immunol 2005; 35: 622-631.
59. - phenotype in developing thymocytes. J Biol Chem 1993; 268: 3801-3804.
60. Hernandez JD, Baum LG. Ah, sweet mystery of death! Galectins and control of cell fate. Glycobiology 2002; 12: 127R-136R.
61. 2+-dependent lectin activity: insights into differential effects of CD45RO and CD45RA T cells. Glycobiology 2006; 16: 173-183.
62. Kaech SM, Hemby S, Kersh E, Ahmed R. Molecular and functional profiling of memory CD8 T cell differentiation. Cell 2002; 111: 837-851.
63. Lim YC, Xie H, Come CE, Alexander SI, Grusby MJ, Lichtman AH et al. IL-12, STAT4-dependent up-regulation of CD4+ T cell core 2 β-1,6-n-acetylglucosaminyltransferase, an enzyme essential for biosynthesis of P-selectin ligands. J Immunol 2001; 167: 4476-4484.
64. Carlow DA, Ardman B, Ziltener HJ. A novel CD8 T cell-restricted CD45RB epitope shared by CD43 is differentially affected by glycosylation. J Immunol 1999; 163: 1441-1448.
65. Hernandez JD, Nguyen JT, He J, Wang W, Ardman B, Green JM et al. Galectin-1 binds different CD43 glycoforms to cluster CD43 and regulate T cell death. J Immunol 2006; 177: 5328-5336.
66. Harrington LE, Galvan M, Baum LG, Altman JD, Ahmed R. Differentiating between memory and effector CD8 T cells by altered expression of cell surface O-glycans. J Exp Med 2000; 191: 1241-1246.
67. Jones AT, Federsppiel B, Ellies LG, Williams M, Burgener R, Duronio V et al. Characterization of the activation-associated isoform of CD43 in murine T lymphocytes. J Immunol 1994; 153: 3426-3439.
68. + T lymphocytes in graft-versus-host disease. Glycobiology 1994; 4: 885-893.
69. Ellies LG, Tao W, Fellinger W, Teh H, Ziltener HJ. The CD43 130-kD peripheral T-cell activation antigen is downregulated in thymic positive selection. Blood 1996; 88: 1725-1732.
70. Baum LG, Pang M, Perillo NL, Wu T, Delegeane A, Uittenbogaart CH et al. Human thymic epithelial cells express an endogenous lectin, galectin-1, which binds to core 2 O-glycans on thymocytes and T lymphoblastoid cells. J Exp Med 1995; 181: 877-887.
71. Mukasa R, Homma T, Ohtsuki T, Honoso O, Souta A, Kitamura T et al. Core 2-containing O-glycans on CD43 are preferentially expressed in the memory subset of human CD4 T cells. Int Immunol 1999; 11: 259-268.
72. Reisner Y, Linker-Israeli M, Sharon N. Separation of mouse thymocytes into two subpopulations by the use of peanut agglutinin. Cell Immunol 1976; 25: 129-134.
73. Barran P, Fellinger W, Warren CE, Dennis JW, Ziltener HJ. Modification of CD43 and other lymphocyte O-glycoproteins by core 2 N-acetylglucosaminyltransferase. Glycobiology 1997; 7: 129-136.
74. Piller F, Piller V, Fox RI, Fukuda M. Human T-lymphocyte activation is associated with changes in O-glycan biosynthesis. J Biol Chem 1988; 263: 15146-15150.
75. Higgins EA, Siminovitch KA, Zhuang D, Brockhausen I, Dennis JW. Aberrant O-linked oligosaccharide biosynthesis in lymphocytes and platelets from patients with the Wiskott-Aldrich syndrome. J Biol Chem 1991; 266: 6280-6290.
76. Rabinovich GA, Daly G, Dreja H, Tailor H, Riera CM, Hirabayashi J et al. Recombinant galectin-1 and its genetic delivery suppress collagen-induced arthritis via T cell apoptosis. J Exp Med 1999; 190: 385-397.
77. Baum LG, Blackall DP, Arias-Magallano S, Nanigian D, Uh SY, Browne JM et al. Amelioration of graft versus host disease by galectin-1. Clin Immunol 2003; 109: 295-307.
78. Lantéri M, Giordanengo V, Hiraoka N, Fuzibet JG, Auberger P, Fukuda M et al. Altered T cell surface glycosylation in HIV-1 infection results in increased susceptibility to galectin-1-induced cell death. Glycobiology 2003; 13: 909-918.
79. Cho M, Cummings RD. Galectin-1, a β-galactoside-binding lectin in chinese hamster ovary cells. J Biol Chem 1995; 270: 5198-5208.
80. Liao DI, Kapadia G, Ahmed H, Vasta GR, Herzberg O. Structure of S-lectin, a developmentally regulated vertebrate β-galactoside-binding protein. Proc Natl Acad Sci USA 1994; 91: 1428-1432.
81. Leppännen A, Stowell S, Blixt O, Cummings RD. Dimeric galectin-1 binds with high affinity to α2,3-sialylated and non-sialylated terminal N-acetyllactosamine units on surface-bound extended glycans. J Biol Chem 2005; 280: 5549-5562.
82. Serrador JM, Nieto M, Alonso-Lebrero JL, del Pozo MA, Calvo J, Furthmayr H et al. CD43 interacts with moesin and ezrin and regulates its redistribution to the uropods of T lymphocytes at the cell-cell contacts. Blood 1998; 91: 4632-4644.
83. Walzel H, Schulz U, Neels P, Brock J. Galectin-1, a natural ligand for the receptor-type protein tyrosine phosphatase CD45. Immunol Lett 1999; 67: 193-202.
84. Fouillit M, Joubert-Caron R, Poirier F, Bourin P, Monostori E, Levi-Strauss M et al. Regulation of CD45-induced signaling by galectin-1 in Burkitt lymphoma B cells. Glycobiology 2000; 10: 413-419.
85. Fortin M, Steff AM, Felberg J, Ding I, Schraven B, Johnson P et al. Apoptosis mediated through CD45 is independent of its phosphatase activity and association with leukocyte phosphatase-associated phosphoprotein. J Immunol 2002; 168: 6084-6089.
86. Hahn HP, Pang M, Hernandez JD, Yang RY, Li LY, Wang X et al. Galectin-1 induces nuclear translocation of endonuclease G in caspase- and cytochrome c-independent T cell death. Cell Death Differ 2004; 11: 1277-1286.
87. Cabrera PV, Amano M, Mitoma J, Chan J, Said J, Fukuda M et al. Haploinsufficiency of C2GnT-I glycosyltransferase renders T lymphoma cells resistant to cell death. Blood 2006; 108: 2399-2406.
88. Stamenkovic I, Sgroi D, Aruffo A, Sy MS, Anderson T. The B lymphocyte adhesion molecule CD22 interacts with leukocyte common antigen CD45RO on T cells and α2,3 sialyltransferase, CD75, on B cells. Cell 1991; 66: 1133-1144.
89. Liu SD, Whiting CC, Tomassian T, Pang M, Bissel SJ, Baum LG et al. Endogenous galectin-1 enforces class I-restricted TCR functional fate decisions in thymocytes. Blood 2008; 112: 120-130.
90. Vespa GNR, Lewis LA, Kozak KR, Moran M, Nguyen JT, Baum LG et al. Galectin-1 specifically modulates TCR signals to enhance TCR apoptosis but inhibit IL-2 production and proliferation. J Immunol 1999; 162: 799-806.
91. Stillman BN, Hsu DK, Pang M, Brewer CF, Johnson P, Liu FT et al. Galectin-3 and galectin-1 bind distinct cells surface glycoprotein receptors to induce T cell death. J Immunol 2006; 176: 778-789.
92. Bi S, Earl LA, Jacobs L, Baum LG. Structural features of galectin-9 and galectin-1 that determine distinct T cell death pathways. J Biol Chem 2008; 283: 11248-11258.
93. Wada J, Ota K, Kumar A, Wallner EI, Kanwar YS. Developmental regulation, expression, and apoptotic potential of galectin-9, a β-galactoside binding lectin. J Clin Invest 1997; 99: 2452-2461.
94. Leitenberg D, Balamuth F, Bottomly K. Changes in the T cell receptor macromolecular signaling complex and membrane microdomains during T cell development and activation. Semin Immunol 2001; 13: 129-138.
95. Hermison ML, Tan AL, Gupta VA, Majeti R, Weiss A. The juxtamembrane wedge negatively regulates CD45 function in B cells. Immunity 2005; 23: 635-647.
96. Xu Z, Weiss A. Negative regulation of CD45 by differential homodimerization of the alternatively spliced isoforms. Nat Immunol 2002; 3: 764-771.
97. Ahmad N, Gabius HJ, André S, Kaltner H, Sabesan S, Roy R et al. Galectin-3 precipitates as a pentamer with synthetic multivalent carbohydrates and forms heterogenous cross-linked complexes. J Biol Chem 2004; 279: 10841-10847.
98. Chen IJ, Chen HL, Demetriou M. Lateral compartmentalization of T cell receptor versus CD45 by galectin-N-glycan binding and microfilaments coordinate basal and activation signaling. J Biol Chem 2007; 282: 35361-35372.
99. Crocker PR, Paulson JC, Varki A. Siglecs and their roles in the immune system. Nat Rev Immunol 2007; 7: 255-266.
100. Zhang M, Varki A. Cell surface sialic acids do not affect primary CD22 interactions with CD45 and surface IgM nor the rate of constitutive CD22 endocytosis. Glycobiology 2004; 14: 939-949.
101. Collins BE, Blixt O, DeSieno AR, Bovin N, Marth JD, Paulson JC. Masking of CD22 by cis ligands does not prevent redistribution of CD22 to sites of cell contact. Proc Natl Acad Sci USA 2004; 101: 6104-6109.
102. Bakker TR, Piperi C, Davies EA, van der Merwe PA. Comparison of CD22 binding to native CD45 and synthetic oligosaccharide. Eur J Immunol 2002; 32: 1924-1932.
103. Van Vliet SJ, Saeland E, van Kooyk Y. Sweet preferences of MGL: carbohydrate specificity and function. Trends Immunol 2008; 29: 83-90.
104. Martínez-Pomares L, Crocker PR, Da Silva R, Holmes N, Colominas C, Rudd P et al. Cell-specific glycoforms of sialoadhesin and CD45 are counter-receptors for the cysteine-rich domain of the mannose receptor. J Biol Chem 1999; 274: 35211-35218.
105. Geijtenbeek TBH, van Vliet SJ, Engering A, Hart BA, van Kooyk Y. Self and nonself-recognition by C-type lectins on dendritic cells. Annu Rev Immunol 2004; 22: 33-54.
106. Varga SM, Welsh RM. The CD45RB-associated epitope defined by monoclonal antibody CZ-1 is an activation and memory marker for mouse CD4 T cells. Cell Immunol 1996; 167: 56-62.